Ozempic's hidden danger: Weight loss drugs may trigger scurvy and severe deficiencies

Weight loss medications such as Ozempic have grown in popularity, but concerns are rising over serious nutritional risks. Doctors now warn that these drugs may lead to deficiencies, causing conditions once thought eliminated, like scurvy. Patients and healthcare providers are being urged to take action before symptoms appear.

The rapid increase in prescriptions for drugs like Ozempic has overshadowed a critical issue: poor nutrition. Many users experience reduced appetite, which can quickly result in deficiencies of essential vitamins and minerals. Symptoms often emerge within two to three months, sometimes mistaken for minor side effects.

Studies highlight cases of vitamin B deficiencies, including Wernicke's encephalopathy, a severe neurological disorder. Reports also mention scurvy, a disease long considered eradicated, resurfacing in patients. Yet, most research on these medications fails to track dietary intake, leaving gaps in understanding the full impact.

In Australia, no verified statistics exist on how many people have developed clinically relevant deficiencies from these drugs. However, global studies on GLP-1 agonists point to common shortfalls in vitamin B12, vitamin D, folate, and protein. To address this, GPs are now advised to refer patients to dieticians when prescribing weight loss medications. Dietary consultations, largely covered by Medicare, can help users maintain a balanced diet while on treatment.

Without proper monitoring, the long-term use of weight loss drugs could lead to chronic health problems, including heart disease and certain cancers. Patients are encouraged to seek dietary support early to prevent deficiencies. The focus must now shift from weight loss alone to ensuring nutritional needs are met.